Skip to Content

Join the 'Glycopyrrolate' group to help and get support from people like you.

Glycopyrrolate News

Sunovion Receives FDA Approval for Lonhala Magnair (glycopyrrolate) Inhalation Solution to Treat COPD

Posted 8 Dec 2017 by Drugs.com

MARLBOROUGH, Mass.--(BUSINESS WIRE) December 5, 2017 --Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution (25 mcg twice daily), also known as SUN-101/eFlow®, for the long-term, maintenance treatment of airflow obstruction in people with chronic ...

Bevespi Aerosphere Approved by the FDA for Patients with COPD

Posted 30 Apr 2016 by Drugs.com

25 April 2016 – AstraZeneca today announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Sean Bohen, Executive ...

FDA Approves Seebri Neohaler (glycopyrrolate) for COPD

Posted 4 Nov 2015 by Drugs.com

EAST HANOVER, N.J., Oct. 29, 2015 Novartis announced today that the US Food and Drug Administration (FDA) has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 mcg as a stand-alone monotherapy for COPD. Novartis expects that Seebri Neohaler will be available in the first quarter of 2016. Seebri is delivered via the low resistance Neohaler inhaler, which makes it suitable for ...

Common Class of Drugs May Be Linked to Pneumonia Risk

Posted 3 Mar 2015 by Drugs.com

TUESDAY, March 3, 2015 – Drugs used to treat a wide range of health problems may be associated with an increased risk of pneumonia, a new study suggests. Anticholinergic medications include those used for conditions such as allergies (for example, Benadryl), overactive bladder (including Ditropan), depression (for example, doxepin) and insomnia (Sominex, etc.). "Our study is the first to address ...

FDA Approves Cuvposa for Chronic Drooling in Children

Posted 2 Aug 2010 by Drugs.com

ROCKVILLE, Md., July 28, 2010--The U.S. Food and Drug Administration today approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years. Drooling is normal in infants. But a significant proportion of the developmentally disabled population experiences drooling caused primarily by neuromuscular dysfunction that ...

Ask a Question

Further Information

Related Condition Support Groups

Excessive Salivation, Anesthesia, Chronic Obstructive Pulmonary Disease, Maintenance, Peptic Ulcer

Related Drug Support Groups

Robinul, Seebri Neohaler, Lonhala Magnair, Robinul Forte, Glycate, Cuvposa

Glycopyrrolate Patient Information at Drugs.com